BI 1015550, Placebo matching BI 1015550, BI 1015550
1305-0023
Phase 3 small_molecule active
Quick answer
BI 1015550, Placebo matching BI 1015550, BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) is a Phase 3 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active